Are all peptides illegal in Australia?

No. Some peptide medicines are registered on the Australian Register of Therapeutic Goods (ARTG) and can be lawfully prescribed and dispensed. Others may be accessed through the Special Access Scheme or Authorised Prescriber pathway under specific clinical conditions. What is illegal is the supply of unapproved peptide products outside these frameworks — including grey-market sales and unlicensed compounding for speculative supply.

Can a compounding pharmacy legally make peptide compounds in Australia?

Compounding pharmacies can lawfully prepare medicines under specific conditions set out in the Therapeutic Goods Act 1989 and TGA guidelines — for example, where a registered product doesn't exist to meet an individual patient's clinical need, under a valid prescription. Large-scale or speculative compounding of peptide products to meet general demand is not lawful under this framework. The TGA issued direct guidance on this from 2023.

What penalties can apply for supplying unapproved peptides?

Under the Therapeutic Goods Act 1989 (Cth), supplying unapproved therapeutic goods can attract civil penalties via infringement notices, formal compliance action including mandatory product recalls, and — for serious or repeat offences — criminal prosecution with significant fines and potential imprisonment. The TGA also works with Australian Border Force to intercept unapproved imports.

What is the 'research chemical' loophole and does it work?

Some suppliers label peptide compounds 'for research use only, not for human use' in an attempt to avoid therapeutic goods regulation. The TGA assesses the intended purpose of a product by how it is presented, marketed, and sold — not solely by label disclaimers. If the marketing context makes clear that a product is intended for human use, the 'research chemical' label does not exclude it from the definition of a therapeutic good, and the supply remains subject to the Act.

How does a medical practitioner legitimately prescribe an unapproved peptide medicine?

An Australian registered medical practitioner can apply to the TGA under the Special Access Scheme (Category B) for approval to supply a specific unapproved therapeutic good to an individual patient, with documented clinical justification. Alternatively, a prescriber may seek Authorised Prescriber status from the TGA, which requires either HREC endorsement or direct TGA approval, and involves ongoing reporting obligations. Both pathways are tightly governed and are not available for general or wellness use outside a clinical relationship.

The TGA Crackdown on Unapproved Peptides

By Priya Nandakumar · 29 June 2026 · 7 min read

a close up of a cell phone with a black background

Somewhere between a Sydney running group and a gym in Neutral Bay, the word "peptide" became shorthand for something you inject before training on a Tuesday. I've been watching this shift for a couple of years , the casual way people reference compounds whose regulatory status they've never looked up. And honestly, the TGA has been watching too. The crackdown that accelerated from 2023 onward wasn't a surprise to anyone paying attention to the Therapeutic Goods Administration's compliance bulletins. But it has caught a lot of people off guard.

Let me be direct about what this article is: a look at the regulatory and chemistry landscape around peptides in Australia, what the TGA's enforcement actions actually target, and why supply of unapproved peptides is illegal , not a grey area, not a technicality, but plainly illegal under the Therapeutic Goods Act 1989 (Cth).

What is a peptide, in the regulatory sense?

A peptide is a short chain of amino acids linked by peptide bonds. That's the chemistry. In the regulatory sense, peptides intended to influence a physiological process in humans are generally classified as biological medicines or prescription-only substances under the Australian Poisons Standard , meaning most of them sit at Schedule 4 (prescription only) or higher.

The TGA's position is not ambiguous. A therapeutic good supplied in Australia must either be listed or registered on the Australian Register of Therapeutic Goods (ARTG), or supplied under a specific access pathway like the Special Access Scheme (SAS) or through an Authorised Prescriber arrangement. If a peptide compound doesn't meet one of those conditions, supplying it is unlawful; full stop.

The class of compounds that attracted the most attention from 2022–2024 includes peptides often marketed for body composition, recovery, and anti-ageing purposes. These products are frequently unapproved in Australia. Supplying them without TGA approval is illegal, and the TGA has made clear it is actively enforcing this.

The enforcement escalation: what the TGA actually did

The TGA's compliance and enforcement activity targeting peptide suppliers picked up substantially in the 2022–2023 financial year. The TGA's published enforcement actions, available on tga.gov.au, document infringement notices, product recalls, and prosecutions directed at businesses and individuals supplying unapproved therapeutic goods including peptide compounds.

The mechanism the TGA relies on is straightforward. Under the Therapeutic Goods Act 1989, it is a criminal offence to supply therapeutic goods that are not included in the ARTG, with penalties including substantial fines and imprisonment for serious or repeated offences. "Supplying" includes selling, agreeing to sell, offering for sale, and even giving. The Act doesn't require proof of harm; the supply of an unapproved good is itself the offence.

The TGA's enforcement tools include:

Infringement notices (on-the-spot civil penalties without prosecution)
Formal warnings and compliance notices
Mandatory recalls of unapproved products
Referral to the Commonwealth Director of Public Prosecutions for criminal proceedings
Border interdiction in cooperation with Australian Border Force

In practice, compounding pharmacies and online retailers have both been targeted. The TGA has specifically flagged businesses that reformulate or repackage peptide compounds into injectable preparations and supply them without the required approvals. That activity does not become lawful because the compound is presented in a clinical-looking vial or sold via a professional-looking website.

GLP-1 receptor agonists: a specific focus

A large share of the recent enforcement attention has fallen on compounds that act as GLP-1 receptor agonists. Without naming specific products, this class of peptide-based compound attracted enormous public interest following high-profile media coverage from 2022 onward. Demand outpaced approved supply. Into that gap came unapproved compounded versions and grey-market imports.

The TGA's position on compounded versions of approved medicines, including peptide-based ones, is that compounding is only lawful when it occurs within the specific regulatory permissions set out in the Act and the relevant guidelines. A compounding pharmacy cannot lawfully produce a large-scale, speculative supply of a therapeutic good equivalent to an approved product simply because demand is high. The TGA issued explicit guidance on this in 2023 and followed with compliance action.

Understanding pharmacokinetics is part of why this matters beyond paperwork. The way a peptide is absorbed, distributed, metabolised, and eliminated depends heavily on its formulation; the excipients, the pH, the vehicle for subcutaneous injection. An unapproved version of a compound that appears chemically similar on paper may behave differently in the body. That's not a hypothetical concern; it is a documented pharmacology consideration. The approval process exists partly to characterise exactly these differences.

Good Manufacturing Practice: why it matters for peptides

Peptides are chemically finicky. That's part of what makes them interesting to study and part of what makes unregulated supply risky. Most therapeutic peptides are vulnerable to degradation, by pH changes, temperature, and enzymatic activity. Maintaining their integrity requires Good Manufacturing Practice (GMP) standards: controlled environments, validated analytical testing, documented batch records, and sterility assurance for injectable preparations.

Products supplied outside the ARTG framework don't have verified GMP backing unless the TGA has assessed them. I'll admit I got this wrong for years as a concept, I assumed "compounded" implied "carefully made." It can, but the word alone guarantees nothing about the standards applied.

GMP is not bureaucratic box-ticking. For an injectable peptide, contamination with endotoxins, incorrect concentration, or degraded active compound are real failure modes with real consequences. The regulatory framework exists to catch these before a product reaches a person. Circumventing it doesn't eliminate those failure modes; it just removes the check.

Who can lawfully access approved peptide medicines?

Some peptide medicines are fully registered on the ARTG. Others may be accessible through the SAS; specifically SAS Category B, which requires an application by a medical practitioner to the TGA, or through the Authorised Prescriber scheme, which allows an eligible prescriber to supply an unapproved therapeutic good to a class of patients after receiving TGA approval to do so.

Neither pathway is a loophole. The SAS requires documented clinical justification. The Authorised Prescriber scheme requires HREC (Human Research Ethics Committee) endorsement or TGA approval and ongoing reporting. These are access pathways for patients with clinical need, overseen by a registered prescriber. They are not a mechanism for general wellness use or for bypassing the ARTG simply because a product is popular.

Schedule 4 prescription-only status means a valid prescription from a registered Australian medical practitioner is required. Schedule 8 status, where some peptide-adjacent compounds sit; adds controlled drug requirements: state/territory permits, stricter prescribing rules, and pharmacist recording obligations under the relevant Poisons and Therapeutic Goods legislation in each jurisdiction.

The "research chemical" framing doesn't hold up

One tactic used to sidestep regulation is labelling peptide compounds as "for research purposes only, not for human use." The TGA has addressed this directly. The intended purpose of a product is assessed by reference to how it is presented, marketed, and sold, not just by a disclaimer printed on a label. If a product is clearly being marketed to individuals for human use, the "research chemical" framing does not exclude it from the definition of a therapeutic good under the Act.

Honestly, I find the persistence of this framing a bit baffling. The TGA's published guidance on this point has been consistent for years. It's not a legal grey area that creative labelling resolves; it's a question of actual use and marketing intent.

What this means for the research landscape

None of this means peptide research itself is being shut down. Clinical trials involving peptide compounds proceed under the Clinical Trial Notification (CTN) and Clinical Trial Exemption (CTX) schemes. Academic and institutional research continues under ethics oversight. The TGA's enforcement targets unlawful commercial supply, not legitimate science.

The peptide class remains scientifically active. Research published via PubMed documents ongoing investigation into peptide mechanisms across multiple biological systems. That research matters. But it proceeds through institutional channels with ethics approval, not through grey-market sales platforms.

For readers curious about the broader regulatory context around bioavailability and how molecular structure affects a compound's absorption pathway, the bioavailability and first-pass metabolism glossary pages give a good grounding. And if you've arrived here from the cannabinoid side of the site; the regulatory logic, while different in specifics, has genuine parallels: scheduled substances, ARTG requirements, and SAS/Authorised Prescriber pathways apply across multiple therapeutic compound classes, not just peptides.

The short version is: if a peptide product is being sold in Australia without ARTG registration, and it's not supplied under a documented SAS or Authorised Prescriber arrangement, its supply is unlawful under Australian law. The TGA is enforcing this. The penalties are real. And the regulatory framework isn't going to loosen just because demand is high, if anything, the trajectory is the other way.

Sources

, Priya Nandakumar, Pharmacology writer, peptides & PK

Common questions

Are all peptides illegal in Australia?: No. Some peptide medicines are registered on the Australian Register of Therapeutic Goods (ARTG) and can be lawfully prescribed and dispensed. Others may be accessed through the Special Access Scheme or Authorised Prescriber pathway under specific clinical conditions. What is illegal is the supply of unapproved peptide products outside these frameworks — including grey-market sales and unlicensed compounding for speculative supply.
Can a compounding pharmacy legally make peptide compounds in Australia?: Compounding pharmacies can lawfully prepare medicines under specific conditions set out in the Therapeutic Goods Act 1989 and TGA guidelines — for example, where a registered product doesn't exist to meet an individual patient's clinical need, under a valid prescription. Large-scale or speculative compounding of peptide products to meet general demand is not lawful under this framework. The TGA issued direct guidance on this from 2023.
What penalties can apply for supplying unapproved peptides?: Under the Therapeutic Goods Act 1989 (Cth), supplying unapproved therapeutic goods can attract civil penalties via infringement notices, formal compliance action including mandatory product recalls, and — for serious or repeat offences — criminal prosecution with significant fines and potential imprisonment. The TGA also works with Australian Border Force to intercept unapproved imports.
What is the 'research chemical' loophole and does it work?: Some suppliers label peptide compounds 'for research use only, not for human use' in an attempt to avoid therapeutic goods regulation. The TGA assesses the intended purpose of a product by how it is presented, marketed, and sold — not solely by label disclaimers. If the marketing context makes clear that a product is intended for human use, the 'research chemical' label does not exclude it from the definition of a therapeutic good, and the supply remains subject to the Act.
How does a medical practitioner legitimately prescribe an unapproved peptide medicine?: An Australian registered medical practitioner can apply to the TGA under the Special Access Scheme (Category B) for approval to supply a specific unapproved therapeutic good to an individual patient, with documented clinical justification. Alternatively, a prescriber may seek Authorised Prescriber status from the TGA, which requires either HREC endorsement or direct TGA approval, and involves ongoing reporting obligations. Both pathways are tightly governed and are not available for general or wellness use outside a clinical relationship.